Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Jun;69(6):2154-2163.
doi: 10.1007/s10620-024-08421-w. Epub 2024 Apr 5.

Correlation Between Serum and Fecal Biomarkers and Patient-Reported Outcomes in Patients with Crohn's Disease and Ulcerative Colitis

Kiran K Motwani  1 , Madeline Alizadeh  2 , Ameer Abutaleb  3 , Jennifer Grossman  2 , Jennifer Wellington  4 , Raymond K Cross  2 ; SPARC-IBD investigators
Collaborators, Affiliations
Multicenter Study

Correlation Between Serum and Fecal Biomarkers and Patient-Reported Outcomes in Patients with Crohn's Disease and Ulcerative Colitis

Kiran K Motwani et al. Dig Dis Sci. 2024 Jun.

Erratum in

Abstract

Background: Patient-reported outcomes (PROs), such as the short CD activity index (sCDAI) and partial Mayo Score (PMS), are used to define clinical remission in IBD, but may not represent the true degree of inflammation and endoscopy is invasive. Non-invasive testing options include c-reactive protein (CRP) and fecal calprotectin (FCP).

Aim: The aim of this study was to assess the degree of correlation of non-invasive biomarkers with PROs and the impact other clinical variables can have on their levels.

Methods: We reviewed data collected from the prospective cohort, Study of a Prospective Adult Research Cohort with IBD (SPARC-IBD), comprised of over 3000 patients from 17 tertiary referral centers. Demographic and clinical variables were analyzed by disease type, disease severity was based on PROs, and baseline CRP and FCP were measured. For comparative analysis, we performed Fisher's exact test and Welch's t test, where p < 0.05 was significant.

Results: 1547 patients were included; 63% had CD, 56% were female, with an average disease duration of 13.6 years. CRP and FCP were associated with symptom severity in inflammatory CD. CRP was useful to differentiate symptoms across different disease locations in CD, whereas FCP was associated with symptom severity in Crohn's colitis only. For UC, FCP was able to distinguish symptom severity better in distal UC, whereas in extensive or pancolitis, it was useful only to distinguish severe symptoms from other categories of symptom severity.

Conclusion: PROs correlate with CRP and FCP; however, disease location and phenotype impact their ability to distinguish symptom severity.

Keywords: C-reactive protein; Crohn’s disease; Fecal calprotectin; Patient-reported outcomes; Ulcerative colitis.

PubMed Disclaimer

References

    1. Moura FA, Fonseca Goulart MO. Chapter 7 - inflammatory bowel diseases: the crosslink between risk factors and antioxidant therapy. In: Gracia-Sancho J, Salvado J, eds. Maceio: Academic Press; 2017; 99–112. - DOI
    1. Henao MP, Bewtra M, Osterman MT et al. Measurement of inflammatory bowel disease symptoms: reliability of an abbreviated approach to data collection. Inflamm Bowel Dis. 2015;21:2262–2271. - PubMed
    1. Kwon HJ, Dudley-Brown S, Williams M et al. Validation of a simple, patient directed, symptom based index for intestinal inflammation. J Clin Gastroenterol Treat. 2016;2:1–5. - DOI
    1. Benitez JM, Meuwis MA, Reenaers C et al. Role of endoscopy, cross-sectional imaging and biomarkers in Crohn’s disease monitoring. Gut. 2013;62:1806–1816. - DOI - PubMed
    1. Bray C, Bell LN, Liang H et al. Erythrocyte sedimentation rate and c-reactive protein measurements and their relevance in clinical medicine. WMJ. 2016;115:317–321. - PubMed

Publication types

LinkOut - more resources